Summary
Gilead Sciences, Inc. reported strong financial performance for the third quarter and first nine months of 2011. Total revenues increased year-over-year, driven by robust sales of its antiviral products, particularly Atripla and Truvada, which together represented a significant portion of total revenue. The company also saw growth in its other therapeutic areas like cardiovascular and respiratory. Gilead announced the U.S. FDA approval of Complera for HIV treatment, further expanding its single-tablet regimen offerings. Significant investments in research and development continued, alongside strategic acquisitions of Arresto Biosciences and Calistoga Pharmaceuticals, bolstering its pipeline in oncology and inflammatory diseases. The company also completed a major stock repurchase program and initiated a new one, demonstrating a commitment to returning capital to shareholders. Financially, Gilead maintained a strong balance sheet with substantial cash, cash equivalents, and marketable securities. Operating cash flow remained healthy, supporting ongoing R&D, acquisitions, and capital returns. While the company faced some challenges, such as decreased royalty revenues from Tamiflu due to declining pandemic planning, and increased SG&A expenses related to acquisitions and the pharmaceutical excise tax, overall performance indicated solid growth and a positive outlook.
Financial Highlights
49 data points| Revenue | $2.12B |
| Cost of Revenue | $531.99M |
| Gross Profit | $1.53B |
| SG&A Expenses | $295.93M |
| Operating Expenses | $1.12B |
| Operating Income | $1.00B |
| Interest Expense | $43.10M |
| Net Income | $441.96M |
| EPS (Basic) | $0.48 |
| EPS (Diluted) | $0.47 |
| Shares Outstanding (Basic) | 1.51B |
| Shares Outstanding (Diluted) | 1.55B |
Key Highlights
- 1Total revenues increased by 11% year-over-year in Q3 2011, reaching $2.12 billion.
- 2Antiviral product sales, particularly Atripla and Truvada, were strong, growing 9% and 11% respectively in Q3 2011, and accounted for a substantial portion of overall revenue.
- 3Gilead received U.S. FDA approval for Complera in August 2011, its second single-tablet regimen for HIV.
- 4The company completed two strategic acquisitions: Arresto Biosciences and Calistoga Pharmaceuticals, enhancing its pipeline in oncology and inflammation.
- 5Research and Development (R&D) expenses increased by 26% in Q3 2011, reflecting continued investment in pipeline development.
- 6The company completed a $5.0 billion stock repurchase program and initiated a new one, with $4.82 billion remaining authorization.
- 7Cash, cash equivalents, and marketable securities stood at $5.48 billion as of September 30, 2011, indicating strong liquidity.